Literature DB >> 361209

Combination chemotherapy of diffuse histiocytic lymphoma with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP).

L Elias, C S Portlock, S A Rosenberg.   

Abstract

Twenty-three patients with diffuse histiocytic lymphoma who had not had prior chemotherapy were treated with CHOP (cyclophosphamide, adriamycin, vincristine, and prednisone). Sixteen of these patients had previously been treated with radiation therapy. Nine of these 23 patients had a pathologically documented complete response at the conclusion of CHOP with an overall complete response rate of 39%. In patients whose disease was confined to lymph nodes, the complete response rate was 7 of 8 or 88%, while in patients with stage IV disease, only 2 of 15 or 13% had complete responses. Although prior radiation therapy could not be demonstrated to be an adverse prognostic factor in this small series, it could have accounted for the low overall complete response rate noted. Complete response in this series was well sustained with an actuarial relapse-free survival of 75% and an actuarial survival of 89% at two years. No complete responses occurred in five patients who had received prior chemotherapy.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 361209     DOI: 10.1002/1097-0142(197810)42:4<1705::aid-cncr2820420408>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  16 in total

1.  Outcome for young high-risk aggressive B-cell lymphoma patients treated with CHOEP-14 and rituximab (R-CHOEP-14).

Authors:  Magdalena Adde; Gunilla Enblad; Hans Hagberg; Christer Sundström; Anna Laurell
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.

Authors:  Charalambos Andreadis; Phyllis A Gimotty; Peter Wahl; Rachel Hammond; Jane Houldsworth; Stephen J Schuster; Timothy R Rebbeck
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

3.  Is the practice of haematology evidence based? I. Evidence based clinical practice.

Authors:  M J Galloway; M M Reid
Journal:  J Clin Pathol       Date:  1998-05       Impact factor: 3.411

4.  Phase II cooperative study with a new alkylating drug, PTT-119, in the treatment of non-Hodgkin's lymphomas.

Authors:  F Gherlinzoni; P Mazza; P L Zinzani; S Tura; F Lanza; G Castoldi; G Bellesi; P L Rossi Ferrini; L Mangoni; V Rizzoli
Journal:  Blut       Date:  1990-03

Review 5.  Gene arrays in lymphoma: Where will they fit in?

Authors:  Javeed Iqbal; Francesco d'Amore; Qinglong Hu; Wing C Chan; Kai Fu
Journal:  Curr Hematol Malig Rep       Date:  2006-06       Impact factor: 3.952

6.  Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.

Authors:  M De Lena; E Maiello; V Lorusso; M Brandi; P Calabrese; S Romito; A Mazzei; F Marzullo
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

Review 7.  Current treatment strategy of diffuse large B-cell lymphomas.

Authors:  Nozomi Niitsu
Journal:  Int J Hematol       Date:  2010-08-28       Impact factor: 2.490

8.  Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo.

Authors:  Yuan Sun; Jack Wu; Amro Aboukameel; Sanjeev Banerjee; Alan A Arnold; Jianyong Chen; Zaneta Nikolovska-Coleska; Yanqiong Lin; Xiaolan Ling; Dajun Yang; Shaomeng Wang; Ayad Al-Katib; Ramzi M Mohammad
Journal:  Cancer Biol Ther       Date:  2008-09-04       Impact factor: 4.742

9.  The treatment of disseminated non-Hodgkin's lymphoma of unfavourable histology.

Authors:  C J Gallagher; A Copplestone; J D Meikle; T A Lister
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  CCNU in combination chemotherapy for advanced histologically unfavorable non-Hodgkin's lymphoma.

Authors:  D V Jackson; H B Muss; F Richards; D R White; C L Spurr; M R Cooper; R M Christian; T F Trahey; L D Case; H B Wells
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.